Leerink Partners Lowers Humana (NYSE:HUM) Price Target to $185.00

Humana (NYSE:HUM) had its price target dropped by equities researchers at Leerink Partners from $267.00 to $185.00 in a report issued on Thursday,MarketScreener reports. The brokerage currently has a “market perform” rating on the insurance provider’s stock. Leerink Partners’ price objective suggests a potential upside of 0.59% from the stock’s previous close.

Several other research firms also recently commented on HUM. Barclays reiterated an “underperformer” rating on shares of Humana in a research report on Monday, January 5th. Royal Bank Of Canada downgraded shares of Humana from an “outperform” rating to a “sector perform” rating and dropped their price target for the company from $322.00 to $189.00 in a research note on Thursday. Weiss Ratings reissued a “sell (d+)” rating on shares of Humana in a research note on Thursday, January 22nd. Jefferies Financial Group lowered their target price on Humana from $313.00 to $310.00 and set a “buy” rating for the company in a research report on Monday, January 26th. Finally, Robert W. Baird cut their target price on Humana from $280.00 to $264.00 and set a “neutral” rating on the stock in a report on Thursday, December 11th. Seven investment analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $239.46.

Humana Stock Up 2.8%

Shares of HUM opened at $183.92 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.02 and a current ratio of 2.00. Humana has a 52 week low of $169.61 and a 52 week high of $315.35. The stock has a market capitalization of $22.12 billion, a price-to-earnings ratio of 18.73, a PEG ratio of 1.99 and a beta of 0.44. The stock has a fifty day moving average of $244.65 and a 200-day moving average of $260.85.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. The business had revenue of $32.64 billion during the quarter, compared to analysts’ expectations of $32.08 billion. Humana had a return on equity of 11.43% and a net margin of 0.92%.The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($2.16) EPS. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. As a group, sell-side analysts anticipate that Humana will post 16.47 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the business. Montag A & Associates Inc. grew its stake in Humana by 1,880.0% during the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the period. CoreCap Advisors LLC boosted its holdings in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana during the 4th quarter worth approximately $27,000. Rosenberg Matthew Hamilton increased its stake in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after acquiring an additional 68 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new stake in shares of Humana in the 2nd quarter valued at $32,000. 92.38% of the stock is owned by institutional investors.

Key Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.